Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion-Reference-Cited by-同舟云学术

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion

Published:2019-11 Issue:11 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Rappo Urania¹,Dunne Michael W.¹,Puttagunta Sailaja¹,Baldassarre James S.¹,Su Shengfang¹,Desai-Krieger Daksha¹,Inoue Megumi²

Affiliation:

1. Allergan plc, Madison, New Jersey, USA

2. SOUSEIKAI Hakata Clinic, Fukuoka, Japan

Abstract

Dalbavancin is a lipoglycopeptide antibiotic with a prolonged half-life. A phase 1 study assessed dalbavancin levels in epithelial lining fluid (ELF) in 35 healthy adults using ELF bronchial microsampling up to 168 h after administration of 1,500 mg dalbavancin. The penetration of dalbavancin into ELF was 36%. ELF levels of dalbavancin exceeded the MIC 90 s of Streptococcus pneumoniae and Staphylococcus aureus for ≥7 days.

Funder

Allergan

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01024-19

Reference16 articles.

1. Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection

2. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection

3. In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin

4. Impact of Glycopeptide Resistance in Staphylococcus aureus on the DalbavancinIn VivoPharmacodynamic Target

5. Dunne M, Koeth LM, Windau AR. 2012. The effect of lung surfactant on the in vitro activity of dalbavancin against Staphylococcus aureus and Streptococcus pneumoniae, poster 1622. ID Week, San Diego, CA.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections;Antibiotics;2023-11-19

2. Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials;Expert Review of Anti-infective Therapy;2023-10-13

3. New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians;Pharmaceuticals;2023-09-15

4. Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections;Pharmaceutics;2022-09-06

5. Determination of plasma protein binding of dalbavancin;Journal of Antimicrobial Chemotherapy;2022-04-30